Pursuing a PhD at the University of Kentucky, Sherif El-Refai divides his time between the doctoral program and conducting lung cancer research at the Black Lab. Sherif El-Refai also serves the Markey Cancer Center as an oncology pharmacist.
In recent news, the Markey Cancer Center published an article about an investigational medical device that received Food and Drug Administration (FDA) approval for clinical trials. The center’s Multidisciplinary Lung Cancer Clinic surgical director and the university’s chief of anesthesiology critical care played crucial roles in developing the Exatherm Total Body Hyperthermia System (Exatherm-TBH) to treat late-stage lung cancer.
Exatherm-TBH delivers heat throughout the body to eliminate cancerous cells. Unlike traditional therapies that only treat affected areas, the system focuses on total body hyperthermia with the use of a perfusion circuit. This allows medical professionals to circulate blood throughout the vascular system at a specific temperature. Because healthy cells have the ability to protect themselves from heightened body temperatures, researchers expect that Exatherm-TBH will be able to attack diseased cells without harming healthy ones.
Sherif El-Refai, who possesses a Doctor of Pharmacy from the University of North Carolina Eshelman School of Pharmacy, has held a number of research and volunteer positions throughout the course of his academic career.